Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of cancer “to incentives created by 340B discounts,” the researchers briefed commissioners during a MedPAC meeting in Washington Jan. 17.
The researchers also said 340B’s effects on cancer drug spending “are likely to be idiosyncratic and not generalizable to other cancers or conditions,” and that 340B’s effect on cost sharing for cancer patents “appears to be small, if any,” depending on the patient’s type of cancer and supplemental insurance coverage.
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
